IFNG and neoplasm: As demonstrated by us, the increased IFN-γ release by the re-stimulation of splenocytes (from tumor-bearing vaccinated mice) with the MSLN peptide supports the hypothesis that an antigen-specific T cell response against PDAC successfully leads to the prevention of disease progression.